Condition: Cardiac Surgery · Vasoplegia · Sponsor: Universität Münster
The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.
This description comes directly from the study's public registry record.
Alexander Zarbock, MD · +49-251-8347252 · PAN-AKI@ukmuenster.de
Melanie Meersch-Dini, MD · +49-251-8347255 · PAN-AKI@ukmuenster.de
Always discuss trial participation with your own doctor first.
| Deutsches Herzzentrum der Charité | Berlin, Germany | Recruiting |
| University Hospital Bonn | Bonn, Germany | Recruiting |
| University Medical Center Mainz | Mainz, Germany | Recruiting |
| University Hospital Münster | Münster, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06615102